Genor Biopharma Holdings (FRA:67N0) Total Current Assets: €125.23 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Total Current Assets?

Genor Biopharma Holdings FRA:67N0 +3.70% 22 Total Current Assets is €125.23 Mil as of Jun. 2025. GuruFocus rates FRA:67N0 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genor Biopharma Holdings's total current assets for the quarter that ended in Jun. 2025 was €125.23 Mil.

Genor Biopharma Holdings  (FRA:67N0) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genor Biopharma Holdings's Liquidation Value for the quarter that ended in Jun. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=121.942-27.299+0.75 * 0+0.5 * 0
=94.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Total Current Assets Related Terms

Genor Biopharma Holdings Total Current Assets Historical Data

* Premium members only.

The historical data trend for Genor Biopharma Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings Total Current Assets Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial 389.85 331.61 232.92 159.40 140.00

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 188.85 159.40 139.86 140.00 125.23
FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genor Biopharma Holdings's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=138.88+-3.49+0+4.605
=140.00

Genor Biopharma Holdings's Total Current Assets for the quarter that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=121.942+3.284+0+0
=125.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €125.23 Mil mean?
Genor Biopharma Holdings (FRA:67N0) has a Total Current Assets of €125.23 Mil as of Jun. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Genor Biopharma Holdings and its competitors.
Is Genor Biopharma Holdings' Total Current Assets too high?
Genor Biopharma Holdings' current Total Current Assets is €125.23 Mil. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' Total Current Assets compare to VRTX and REGN?
Genor Biopharma Holdings' Total Current Assets of €125.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Genor Biopharma Holdings and its competitors. Genor Biopharma Holdings's current Total Current Assets is €125.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current Total Current Assets of €125.23 Mil. The current Total Current Assets is €125.23 Mil. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current Total Current Assets is €125.23 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price